| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -4.9 | -0.3 |
| EPS (diluted, $ a share) | $-0.47 | $-0.05 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: VOGX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Vogenx, Inc.: key numbers
- Share price
- $14.38Close, Nov 16
- Market cap
- $214M
- Shares outstanding
- 14.86MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Vogenx, Inc.
All →Vogenx Financial Results
Vogenx reported Q3 2026 financial results, its first as a public company following a $93.4 million IPO in August. The company ended the quarter with $82.1 million in cash and initiated its Phase 2b EMERGE study for mizagliflozin in post-bariatric hypoglycemia.
- Term
- Q3 2026
“Our third quarter performance marks a pivotal milestone for Vogenx following our successful public listing in August. The EMERGE study is now up and running and we have added critical headcount across the Company, positioning us to advance the development of mizagliflozin for both post-bariatric hypoglycemia (PBH) and gastroparesis.”
James Green, Chief Executive Officer of Vogenx
Vogenx Leadership Change
Richard Gorman has been appointed as Chief Commercial Officer of Vogenx, Inc., effective October 12, 2026. Concurrent with this appointment, Mr. Gorman resigned from his position as an independent member of the Board of Directors and its committees. The company will conduct a search for a new independent director to fill the board vacancy.
Vogenx Leadership Change
Vogenx, Inc. appointed Ken Toombs to its Board of Directors as an independent director and Chair of the Audit Committee, effective September 21, 2026. Mr. Toombs, the former CEO of PA Consulting, brings thirty years of experience in professional services and life sciences to the board as the company scales operations following its August 2026 IPO. Peter Pieraccini was also appointed to serve as Chair of the Compensation Committee.
- Counterparty
- Ken Toombs